Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy
<h3>Introduction</h3><h4>Cancer Immunotherapy has recently emerged as a promising and effective modality to treat different malignancies. Antigenic profiling of cancer tissues and determination of any pre-existing immune responses to cancer antigens may help predict responses to im...
محفوظ في:
| المؤلف الرئيسي: | Afsheen Raza (492657) (author) |
|---|---|
| مؤلفون آخرون: | Maysaloun Merhi (4246147) (author), Varghese Philipose Inchakalody (14153292) (author), Roopesh Krishnankutty (1297770) (author), Allan Relecom (14153295) (author), Shahab Uddin (154400) (author), Said Dermime (14153298) (author) |
| منشور في: |
2022
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
مواد مشابهة
-
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
حسب: Remy Thomas (702843)
منشور في: (2018) -
Editorial: Cancer testis antigens in cancer: Recent developments as cancer biomarkers and therapeutic targets
حسب: Adviti Naik (673163)
منشور في: (2022) -
Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?
حسب: Ghaneya Al-Khadairi (14153274)
منشور في: (2019) -
Commentary: Cancer-testis antigen lactate dehydrogenase C4 as a novel biomarker of male infertility and cancer
حسب: A. Naik (7783220)
منشور في: (2023) -
Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapy
حسب: Remy Thomas (702843)
منشور في: (2020)